Spots Global Cancer Trial Database for light chain deposition disease
Every month we try and update this database with for light chain deposition disease cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Rifaximin in Patients With Monoclonal Gammopathy | NCT03820817 | IgA Monoclonal ... IgG Monoclonal ... IgM Monoclonal ... Light Chain Dep... Monoclonal Gamm... Smoldering Wald... Waldenstrom Mac... Gammopathy, Mon... Gammopathy Igg | Rifaximin | 18 Years - | Emory University | |
| HD Melphalan and SCT in Patients With IGDD or LCDD | NCT00681044 | Multiple Myelom... | filgrastim melphalan Stem Cell Infus... | 18 Years - 120 Years | Boston Medical Center | |
| A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH | NCT05283993 | Multiple Myelom... Amyloidosis Cryoglobulinemi... Castleman's Dis... Light Chain Dep... Heavy Chain Dep... Polyneuropathy ... Smoldering Mult... Plasma Cell Leu... Monoclonal Gamm... Monoclonal Gamm... Monoclonal Gamm... | No intervention | - | Peking University First Hospital | |
| Rifaximin in Patients With Monoclonal Gammopathy | NCT03820817 | IgA Monoclonal ... IgG Monoclonal ... IgM Monoclonal ... Light Chain Dep... Monoclonal Gamm... Smoldering Wald... Waldenstrom Mac... Gammopathy, Mon... Gammopathy Igg | Rifaximin | 18 Years - | Emory University | |
| A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH | NCT05283993 | Multiple Myelom... Amyloidosis Cryoglobulinemi... Castleman's Dis... Light Chain Dep... Heavy Chain Dep... Polyneuropathy ... Smoldering Mult... Plasma Cell Leu... Monoclonal Gamm... Monoclonal Gamm... Monoclonal Gamm... | No intervention | - | Peking University First Hospital | |
| Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma | NCT01169337 | Light Chain Dep... Smoldering Mult... | Clinical Observ... Lenalidomide Quality-of-Life... | 18 Years - | National Cancer Institute (NCI) | |
| Registry for Adults With Plasma Cell Disorders (PCD's) | NCT03717844 | Multiple Myelom... Amyloidosis Cryoglobulinemi... Castleman's Dis... Light Chain Dep... Heavy Chain Dep... Polyneuropathy ... Smoldering Mult... Plasma Cell Leu... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | ||
| Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT01533194 | Light Chain Dep... Refractory Plas... | Diagnostic Labo... Wild-type Reovi... | 18 Years - | National Cancer Institute (NCI) | |
| First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD | NCT01728259 | Light Chain Dep... Primary Systemi... | pomalidomide bortezomib dexamethasone Laboratory Biom... | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma | NCT01849783 | Extramedullary ... Isolated Plasma... Light Chain Dep... Primary Systemi... Stage I Multipl... Stage II Multip... Stage III Multi... | dexamethasone cisplatin doxorubicin cyclophosphamid... etoposide bortezomib thalidomide melphalan autologous stem... | 65 Years - 85 Years | University of Iowa | |
| Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma | NCT01849783 | Extramedullary ... Isolated Plasma... Light Chain Dep... Primary Systemi... Stage I Multipl... Stage II Multip... Stage III Multi... | dexamethasone cisplatin doxorubicin cyclophosphamid... etoposide bortezomib thalidomide melphalan autologous stem... | 65 Years - 85 Years | University of Iowa | |
| Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis | NCT01078454 | Light Chain Dep... Primary Systemi... | melphalan dexamethasone bortezomib | 18 Years - | National Cancer Institute (NCI) | |
| HD Melphalan and SCT in Patients With IGDD or LCDD | NCT00681044 | Multiple Myelom... | filgrastim melphalan Stem Cell Infus... | 18 Years - 120 Years | Boston Medical Center | |
| Detecting Early Myocardial Infiltration w/Amyloid & Light Chain Deposition Disease in Multiple Myeloma Subjects | NCT01018927 | Multiple Myelom... | Administering t... | 18 Years - 80 Years | University of Arkansas | |
| Registry for Adults With Plasma Cell Disorders (PCD's) | NCT03717844 | Multiple Myelom... Amyloidosis Cryoglobulinemi... Castleman's Dis... Light Chain Dep... Heavy Chain Dep... Polyneuropathy ... Smoldering Mult... Plasma Cell Leu... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | ||
| Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease | NCT00520767 | Primary Systemi... Light Chain Dep... | bortezomib dexamethasone melphalan microarray anal... flow cytometry laboratory biom... quality-of-life... | 18 Years - 120 Years | Barbara Ann Karmanos Cancer Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
